Literature DB >> 20339029

Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21.

Jacqueline D Shields1, Iraklis C Kourtis, Alice A Tomei, Joanna M Roberts, Melody A Swartz.   

Abstract

Tumor manipulation of host immunity is important for tumor survival and invasion. Many cancers secrete CCL21, a chemoattractant for various leukocytes and lymphoid tissue inducer cells, which drive lymphoid neogenesis. CCL21 expression by melanoma tumors in mice was associated with an immunotolerant microenvironment, which included the induction of lymphoid-like reticular stromal networks, an altered cytokine milieu, and the recruitment of regulatory leukocyte populations. In contrast, CCL21-deficient tumors induced antigen-specific immunity. CCL21-mediated immune tolerance was dependent on host rather than tumor expression of the CCL21 receptor, CCR7, and could protect distant, coimplanted CCL21-deficient tumors and even nonsyngeneic allografts from rejection. We suggest that by altering the tumor microenvironment, CCL21-secreting tumors shift the host immune response from immunogenic to tolerogenic, which facilitates tumor progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20339029     DOI: 10.1126/science.1185837

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  213 in total

Review 1.  The lymphatic vasculature in disease.

Authors:  Kari Alitalo
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

Review 2.  New insights into the development of lymphoid tissues.

Authors:  Serge A van de Pavert; Reina E Mebius
Journal:  Nat Rev Immunol       Date:  2010-08-13       Impact factor: 53.106

3.  Tumour immunology: Promoting tolerance.

Authors:  Sarah Seton-Rogers
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

4.  IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46.

Authors:  Maya Eisenring; Johannes vom Berg; Glen Kristiansen; Elisabeth Saller; Burkhard Becher
Journal:  Nat Immunol       Date:  2010-10-10       Impact factor: 25.606

Review 5.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

Review 6.  Advancing islet transplantation: from engraftment to the immune response.

Authors:  R F Gibly; J G Graham; X Luo; W L Lowe; B J Hering; L D Shea
Journal:  Diabetologia       Date:  2011-08-10       Impact factor: 10.122

Review 7.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

8.  Intratumoral accumulation of podoplanin-expressing lymph node stromal cells promote tumor growth through elimination of CD4+ tumor-infiltrating lymphocytes.

Authors:  Aikaterini Hatzioannou; Saba Nayar; Anastasios Gaitanis; Francesca Barone; Constantinos Anagnostopoulos; Panayotis Verginis
Journal:  Oncoimmunology       Date:  2016-07-29       Impact factor: 8.110

9.  B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity.

Authors:  Ming-Ru Wu; Tong Zhang; Albert T Gacerez; Tiffany A Coupet; Leslie R DeMars; Charles L Sentman
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

10.  Lymphatic vessels regulate immune microenvironments in human and murine melanoma.

Authors:  Amanda W Lund; Marek Wagner; Manuel Fankhauser; Eli S Steinskog; Maria A Broggi; Stefani Spranger; Thomas F Gajewski; Kari Alitalo; Hans P Eikesdal; Helge Wiig; Melody A Swartz
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.